Gonadorelin.
Gonadorelin is a synthetic decapeptide identical in sequence to endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic hormone that governs the reproductive hypothalamic-pituitary-gonadal axis.
Gonadorelin is a synthetic decapeptide identical in sequence to endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic hormone that governs the reproductive hypothalamic-pituitary-gonadal axis. Gonadorelin is fda-approved, and PepCue grades its published evidence A tier (80/100). Also known as GnRH · Factrel. This is a research reference, not medical or dosing advice.
What it is
Gonadorelin is a synthetic decapeptide identical in sequence to endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic hormone that governs the reproductive hypothalamic-pituitary-gonadal axis. It is made as gonadorelin hydrochloride or acetate and has an extremely short circulating half-life of roughly 2 to 10 minutes. Historically it was used in humans both as a diagnostic agent (the GnRH stimulation test, marketed as Factrel) and, in pulsatile-pump form, to treat infertility from hypothalamic causes. Today it is also widely encountered as a compounded product, often paired with testosterone therapy.
How it works
Gonadorelin binds GnRH receptors on pituitary gonadotrope cells, triggering release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Because the natural hormone is secreted in pulses, the pattern of delivery is decisive: brief, intermittent (pulsatile) exposure sustains LH and FSH secretion, whereas continuous exposure desensitizes and down-regulates the receptor, paradoxically suppressing gonadotropins. This pulsatile-versus-continuous distinction is why the same target can be used either to stimulate the axis (pulsatile pumps) or, via long-acting GnRH agonists, to shut it down in prostate cancer and endometriosis. Downstream, LH and FSH drive gonadal production of testosterone or estrogen and support sperm and egg development.
Mechanism pathways
Driving the pituitary and gonadal end of the reproductive hormone axis.
The reproductive axis runs in three stages. Gonadotropin-releasing hormone is secreted in pulses from the hypothalamus and acts on GnRH receptors on pituitary gonadotrope cells. Those cells release luteinizing hormone and follicle-stimulating hormone. LH and FSH then act on the gonads: in males LH drives Leydig cells to produce testosterone while FSH supports Sertoli cells and sperm production, and in females they govern follicular development, ovulation, and corpus luteum function. Sex steroids feed back on both the hypothalamus and pituitary to close the loop. The single most important feature of this pathway is that the pattern of stimulation determines the outcome, not just its presence. Brief, intermittent, pulsatile exposure to GnRH sustains LH and FSH release. Continuous exposure desensitises and downregulates the receptor, which after an initial surge shuts gonadotropin secretion down. This is why the same receptor is used both to switch the axis on, through pulsatile delivery, and to switch it off, through long-acting agonists used in prostate cancer, endometriosis, and precocious puberty. Anyone reasoning about a GnRH-targeting compound who ignores the delivery pattern will reach the wrong conclusion. Compounds here act at different levels. One is the natural decapeptide itself, engaging pituitary GnRH receptors directly. Another acts a step downstream: it is structurally similar to LH and binds the shared LH and chorionic gonadotropin receptor on gonadal cells, effectively substituting for LH and stimulating testosterone production or triggering final oocyte maturation depending on context. A third acts a step upstream, on the neurons that release GnRH in the first place. Because these compounds enter the axis at different points, they behave differently. Acting at the pituitary preserves gonadal feedback; acting directly on the gonad bypasses the pituitary entirely and does not require a functioning pituitary to work. Clinical grounding here is comparatively strong. Members of this group are approved medicines with defined indications in fertility medicine and endocrinology, and the physiology has been demonstrated in humans over decades. That established status applies to specific supervised medical uses. It does not extend to unsupervised use for hormone manipulation outside those indications, where dosing pattern errors can produce the opposite of the intended effect, and where suppression of the axis rather than stimulation is a real possibility.
The evidence
Pulsatile GnRH therapy has decades of clinical use for inducing ovulation in women with hypothalamic amenorrhea and for restoring fertility in men with congenital hypogonadotropic hypogonadism, and its physiology is well characterized in the endocrine literature. Reviews such as the 2019 Endocrine Reviews synthesis on congenital hypogonadotropic hypogonadism, and reports on pulsatile GnRH in hypothalamic amenorrhea, document reproducible gonadotropin and fertility responses. Most of that literature consists of specialist case series, cohort studies and expert reviews accumulated over decades rather than large modern randomised trials, and it depends on pump-delivered pulsatile administration in patients whose defect is hypothalamic and whose pituitary is intact. As a diagnostic (GnRH stimulation) agent, its ability to provoke measurable LH and FSH release is well established. Evidence for the newer trend of pairing low-dose gonadorelin with testosterone replacement to preserve testicular function is far thinner and largely extrapolated rather than proven in dedicated trials. In short, the strongest evidence supports the classic fertility and diagnostic uses, while other uses are less well supported. Two comparisons make the evidence gap concrete. First, long-acting GnRH agonists and GnRH antagonists, which act at the same receptor to suppress rather than stimulate the axis, were approved on the basis of registrational randomised trials in prostate cancer, endometriosis and assisted reproduction, so the suppressive side of GnRH pharmacology is far better documented than stimulatory gonadorelin use. Second, for maintaining testicular function during androgen therapy, HCG has approved labelling and a substantial published clinical record because it stimulates the LH receptor directly, whereas gonadorelin depends on an intact pituitary and on delivery that mimics natural pulses. Randomised head-to-head comparisons of gonadorelin against HCG for that purpose, and controlled outcome data on sperm parameters or fertility, are not available.
The evidence, in brief
A synthetic decapeptide identical to natural GnRH, with a half-life of only minutes. Its best evidence is in the classic uses: the GnRH stimulation test and pulsatile therapy for hypothalamic amenorrhea and congenital hypogonadotropic hypogonadism, where the delivery pattern is decisive because continuous exposure suppresses rather than stimulates the axis. The human FDA-approved products (Factrel, Lutrepulse) are discontinued in the US, so present-day access is largely compounded, and the popular pairing with testosterone therapy rests on extrapolation rather than dedicated trials.
- Young J et al.: Clinical Management of Congenital Hypogonadotropic HypogonadismEndocr Rev, 2019 (PMID 30698671)
- Christou F et al.: Induction of ovulation by pulsatile GnRH in hypothalamic amenorrheaGynecol Endocrinol, 2017 (PMID 28277105)
- DailyMed label search: gonadorelinFDA / DailyMed
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #026
Meaningful human evidence; not yet definitive.
FDA-approved for a specific indication: the strongest lane.
Claim receipts
Popular claims about Gonadorelin, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Decades of pulsatile pump therapy support this in patients with an intact pituitary, but the literature is specialist case series and expert reviews rather than modern randomized trials.
Only pulsatile delivery sustains LH and FSH release; continuous exposure desensitizes the receptor and suppresses the gonadotropins it is meant to raise.
No randomized head-to-head comparison or controlled outcome data on sperm parameters exists for this use.
The approved human products were discontinued, and present-day human material comes from compounding pharmacies or research-chemical channels.
Safety profile
In pulsatile fertility use gonadorelin is generally well tolerated; reported effects include injection-site reactions and, with pump therapy, a risk of ovarian hyperstimulation and multiple pregnancy that requires monitoring. Rare hypersensitivity and anaphylaxis-type reactions have been described. Supervised use therefore involves serial hormone measurement and, in ovulation induction, ultrasound follicle tracking, since the point of the therapy is to drive an endocrine axis whose output can overshoot. Because it works through the body's own hormonal axis, its effects depend heavily on the dose pattern and on individual physiology, and the pulsatile versus continuous distinction is a safety issue as well as an efficacy one: non-pulsatile exposure can desensitise pituitary receptors and suppress the very gonadotropins the treatment aims to raise. Supply is a further consideration. The FDA-approved human gonadorelin products were discontinued, so present-day human material comes from compounding pharmacies or, in the grey market, from research-chemical vendors. Compounded preparations are not subject to the batch-level approval, stability testing and labelling standards applied to approved drugs, and research-grade vials carry no assurance of identity, potency, purity or sterility at all. That matters for a peptide with a very short half-life, where the delivered pattern and actual content determine whether the effect is stimulatory, negligible or suppressive. This is educational information only and not a dosing or treatment guide; hormonal therapies should be overseen by a qualified clinician.
Compound notes
- Gonadorelin is a synthetic decapeptide identical in sequence to endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic hormone that governs the reproductive axis.
- It binds GnRH receptors on pituitary gonadotropes, triggering release of LH and FSH, which in turn drive gonadal testosterone or estrogen production and support sperm and egg development.
- Its circulating half-life is very short, roughly 2 to 10 minutes.
- The delivery pattern is decisive: brief, intermittent exposure sustains LH and FSH secretion, while continuous exposure desensitizes and down-regulates the receptor, paradoxically suppressing gonadotropins.
The same receptor can switch the axis on or off. Pulsatile delivery stimulates fertility; long-acting GnRH agonists exploit continuous exposure to shut the axis down in prostate cancer and endometriosis.
- The FDA-approved human products (Factrel for the GnRH stimulation test, Lutrepulse for pulsatile ovulation induction) have been discontinued in the US; present-day human access is largely through compounding pharmacies.
- Reported effects include injection-site reactions and, with pump therapy, risk of ovarian hyperstimulation and multiple pregnancy; rare hypersensitivity and anaphylaxis-type reactions have been described.
- Evidence for pairing it with testosterone therapy to preserve testicular function is thin and largely extrapolated rather than proven in dedicated trials.
Regulatory status
Gonadorelin was FDA-approved for humans in the 1980s, including Factrel (gonadorelin hydrochloride) for the GnRH stimulation test and Lutrepulse for pulsatile ovulation induction, but these human products have since been discontinued in the US market. DailyMed currently lists gonadorelin only in approved veterinary products (for example Factrel, Cystorelin, Fertagyl), and present-day human access is largely through compounding pharmacies. It remains a recognized drug substance rather than a dietary supplement.
Approved by the FDA for at least one indication.
By the numbers
- 01Synthetic decapeptide identical to natural GnRH (gonadotropin-releasing hormone)
- 02Stimulates pituitary release of LH and FSH
- 03Only pulsatile delivery stimulates the axis; continuous exposure suppresses it
- 04Very short half-life, roughly 2 to 10 minutes
- 05FDA-approved human products (Factrel, Lutrepulse) are discontinued; now mostly compounded
- 06Classic uses are the GnRH stimulation test and pulsatile fertility therapy
Gonadorelin: research formats
Choose the format you are researching to see route-specific notes.
Half-life of 2 to 10 minutes means pulsatile delivery is the whole point of the format.
Gonadorelin is synthetic GnRH with a circulating half-life of roughly 2 to 10 minutes. The US human products are discontinued: Factrel was used for the GnRH stimulation test and Lutrepulse delivered the peptide in pulses through a portable pump for ovulation induction. Present-day human access is largely through compounding pharmacies. The historical labeled diagnostic format below is a public regulatory fact.
Pulsatility is not a scheduling preference, it is the mechanism. Pulsed exposure stimulates the pituitary to release LH and FSH, while continuous exposure suppresses the axis, which is exactly how long-acting GnRH agonists are used to shut it down.
DailyMed currently lists gonadorelin only in approved veterinary products. Compounded human preparations are dispensed on a prescription and are not FDA-approved finished drugs.
Sources
Every factual claim above resolves to a real, published source.
- Clinical Management of Congenital Hypogonadotropic HypogonadismYoung J, et al. Endocr Rev. 2019 (PMID 30698671)
- Induction of ovulation by pulsatile administration of GnRH in hypothalamic amenorrheaChristou F, et al. Gynecol Endocrinol. 2017 (PMID 28277105)
- DailyMed label search: gonadorelinFDA/NLM DailyMed structured product labels
- Gonadorelin and GnRH clinical trial registrations (ClinicalTrials.gov search)ClinicalTrials.gov registry search
- Human chorionic gonadotropin for maintaining testicular function during testosterone therapy (PubMed search)PubMed search results
- GnRH agonists and antagonists: clinical pharmacology (PubMed search)PubMed search results
Cite this page
PepCue. “Gonadorelin: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/gonadorelin.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.